Highest-materiality recent filing
ABVC BioPharma concludes Q3 2025 financials unreliable; total assets surge 179% to $21.06M
Board determined Q3 2025 financials unreliable due to revenue recognition errors ($795,950 reversed) and land valuation error ($798,486 increase).
ABVC BioPharma completes $2.28M additional unregistered offering, issues 1.5M shares
From May 26, 2025 to Jan 6, 2026, ABVC accepted additional subscriptions totaling $2,275,468 under same terms as prior Reg S offering.
ABVC BioPharma Q3 2025 licensing revenue up 230% YoY to $1.28M; total assets rise 181%
Licensing revenue of $1.28M in Q3 2025 vs $0.39M in Q3 2024 (+230% YoY).
ABVC Biopharma: Former auditor WWC refused to provide letter agreeing with 8-K statements
WWC, P.C. agreed not to renew engagement on October 10, 2024.
ABVC BioPharma reports Q2 2025 results with 103% asset growth and $350K licensing revenue
Total consolidated assets increased 103% to $16.2 million from $8.0 million in Q2 2024
ABVC issues 2.04M shares + 1M warrants for Taiwan land from director Shuling Jiang
Issued 2,035,136 restricted shares to Jiang for land valued at $3.86M, plus assumption of $500K bank liability.
ABVC BioPharma accepts additional $670K in Reg S offering, issuing 957,144 shares
Initial Reg S offering (Apr 30–May 9) sold 1,030,413 shares for aggregate gross proceeds ~$619,625.
ABVC BioPharma regains Nasdaq minimum bid price compliance; reports 234% revenue growth in FY2024
Regained compliance after maintaining $1.00 bid price for 10 consecutive days through May 12, 2025.
ABVC BioPharma regains Nasdaq compliance after equity shortfall notice
On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).
ABVC BioPharma says 2023 financials error resolved in filed 10-K, no amendment needed
Original 8-K on Apr 15, 2025 flagged 2023 financials for errors, requiring amendment.
ABVC receives Nasdaq delisting notice for low equity; raises $436K in stock sale
Nasdaq notified ABVC on April 24 that stockholders' equity of $723,959 is below the $2.5M minimum for continued listing.
ABVC FY2024 revenue $509.6K (+234%), net loss narrows 77% to $4.9M, EPS $(0.42)
Revenue surged 234% to $509,589 driven by licensing milestones.
ABVC BioPharma reports 2024 revenue up 234%, EPS improves 77%, but restates FY2023 financials
Revenue $509,589 (+234% YoY); net loss narrowed to $4.90M; EPS improved 77% to ($0.42).
CFO Leeds Chow resigns; CEO Uttam Patil named interim CFO
Leeds Chow resigned as CFO of ABVC Biopharma effective March 5, 2025.
ABVC BioPharma auditor WWC P.C. declines renewal; Simon & Edward LLP appointed
WWC agreed not to renew engagement effective Oct 10, 2024; Board approved non-renewal on Oct 17.
ABVC BioPharma Q2 2024 EPS improves 86.8% to -$0.09; licensing deals worth up to $292M
EPS improved 86.8% YoY to -$0.09 in Q2 2024 from -$0.68; revenue surged to $117,142 from $6,109.
ABVC BioPharma CFO suspends work amid salary dispute; company corrects license fee numbers downward
CFO Leeds Chow suspends work due to disagreements over salary owed; CEO Uttam Patil becomes interim CFO.
ABVC BioPharma receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on July 10, 2024 for non-compliance with minimum $1.00 bid price rule over 30 consecutive days.
ABVC Biopharma induces Lind Global to exercise 1M warrants at $0.75, issues new 1M warrant at $1.00
Lind Global exercises 1,000,000 existing warrants at reduced price of $0.75/share, generating $750,000 cash proceeds.
ABVC BioPharma terminates land transfer agreement with director Shuling Jiang
Board terminated agreement to acquire land in Taoyuan City, Taiwan from director Shuling Jiang on May 16, 2024.
ABVC licenses BLEX 404 to OncoX for pancreatic cancer; up to $13.75M in fees plus royalties
ABVC grants OncoX exclusive rights to develop/commercialize BLEX 404 for pancreatic cancer in 50% of worldwide markets for 20 years.
20-year exclusive global license with ForSeeCon Eye Corp for ophthalmology pipeline including Vitargus.
ABVC BioPharma FY2023 revenue falls 84% to $152K; net loss narrows to $10.9M
Revenue of $152,430 in FY2023, down from $969,783 in FY2022; net loss improved 31% to $10.9M.
On March 5, 2025, Mr. Leeds Chow, the Chief Financial Officer (“CFO”) of ABVC BioPharma, Inc. (the “Company”) notified the Company of his resignation as CFO.
While the Company is looking for a full-time Chief Financial Officer to fill the vacancy created by Leeds Chow’s resignation, the Company’s CEO, Uttam Patil will serve as the interim Chief Financial Officer of the Company.
due to disagreements regarding salaries due and payable, Mr. Chow has informed the Company that he is suspending his work as CFO.
The Company’s CEO, Uttam Patil, will assume the duties of interim Chief Financial Officer until the parties settle the disagreement and Leeds resumes his position as CFO.
Max materiality 0.90 · Median 0.60 · Most common event other_material